All In Biotech

Drug Trial Radar · NCT06016972

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

A Randomized, Multi-site, Double-masked Study Evaluating the Safety and Tolerability of QLS-111 Vs Vehicle in Primary Open-angle Glaucoma or Ocular Hypertension Patients

Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

63

Actual

Start

Mar 5, 2024

Primary completion

Aug 20, 2024

Study completion Aug 20, 2024

Sponsor

Lead sponsor
Qlaris Bio, Inc.Industry
Sponsor type
Industry
First posted
Aug 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.

Conditions

  • Primary Open Angle Glaucoma (POAG)
  • Primary Open Angle Glaucoma of Both Eyes
  • Primary Open-Angle Glaucoma, Unspecified Eye
  • Ocular Hypertension (OHT)

Interventions

  • Experimental: QLS-111 ophthalmic solution, (0.015%)Drug

    QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

  • Experimental: QLS-111 ophthalmic solution, (0.03%)Drug

    QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

  • Experimental: QLS-111 ophthalmic solution, (0.075%)Drug

    QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

  • QLS-111 ophthalmic vehicle solutionOther

    Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs)Time frame: 21 days
  2. Clinically significant change in visual acuityTime frame: 21 days
  3. Clinically significant change in findings on slit lamp examTime frame: 21 days
  4. Clinically significant change in findings on fundus examTime frame: 21 days
  5. Incidence of systemic TEAEsTime frame: 21 days
  6. Clinically significant changes in blood pressure (BP)Time frame: 21 days
  7. Clinically significant changes in heart rate (HR)Time frame: 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Coastal Research Associates, LLC

    Roswell, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.